Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

191.98 -1.83 (-0.94%)
Streaming Delayed Price Updated: 12:43 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
News headline image
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
From Biogen Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen to Realign Resources for Alzheimer's Disease Franchise
From Biogen Inc.
Via GlobeNewswire
News headline image
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
News headline image
5 Biotech stocks tapping into unmet mental health treatment needs
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. 
Via MarketBeat
News headline image
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
From Biogen Inc.
Via GlobeNewswire
News headline image
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Appoints Monish Patolawala to its Board of Directors
Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation 
From Biogen Inc.
Via GlobeNewswire
News headline image
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
News headline image
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
From Biogen Inc.
Via GlobeNewswire
News headline image
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Completes Acquisition of Reata Pharmaceuticals
From Biogen Inc.
Via GlobeNewswire
News headline image
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Appoints Jane Grogan as Head of Research
From Biogen Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.